Clinical Trial Search

Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg

Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05

Primary: Incidence of Adverse Events — 3; 4 Participants

Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation

Primary: Mean Percent Electronically Monitored Medication Adherence Over Six Months — 77.6; 58.0 percent adherence — p=<0.001

Primary: Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma — 9; 12 participants

Primary: Glaucoma Medication Adherence — 72 percentage of adherence time

Primary: Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1 — -8.5; -4.9 mmHg — p=0.0644

Primary: Change in Intraocular Pressure (IOP) From Baseline to Week 1 — -8.3 mmHg — p=0.0004

Primary: Mean Change From Baseline in BCVA at Week 8 — 6.4; 6.5 Letters

Primary: Change in Best Corrected Visual Acuity by Early Treatment Diabetic Retinopathy Study Chart Visual Scale Testing — 4.5 Change in letters (BCVA)

Primary: Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing — 2.7 Change in letters (BCVA)

Primary: Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — 0.1; 1.0 Letters correctly read

Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2

Primary: Change in Best Corrected Visual Acuity — 6.0; 4.6 Change in letters (BCVA)